Skip to main content

Research Repository

Advanced Search

Outputs (63)

Removal of Human Leukemic Cells from Peripheral Blood Mononuclear Cells by Cell Recognition Chromatography with Size Matched Particle Imprints (2020)
Journal Article
Chester, R., Das, A. A. K., Medlock, J., Nees, D., Allsup, D. J., Madden, L. A., & Paunov, V. N. (2020). Removal of Human Leukemic Cells from Peripheral Blood Mononuclear Cells by Cell Recognition Chromatography with Size Matched Particle Imprints. ACS Applied Bio Materials, 3(2), 789-800. https://doi.org/10.1021/acsabm.9b00770

We report a cell recognition chromatography approach for blood cancer cell separation from healthy peripheral blood mononuclear cells (PBMCs) based on sizematched functionalized particle imprints. Negative imprints were prepared from layers of 15 μm... Read More about Removal of Human Leukemic Cells from Peripheral Blood Mononuclear Cells by Cell Recognition Chromatography with Size Matched Particle Imprints.

Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population (2024)
Journal Article
Molica, S., Shanafelt, T. D., Allsup, D., & Giannarelli, D. (2024). Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population. Cancers, 16(6), Article 1085. https://doi.org/10.3390/cancers16061085

To assess the impact of first-line treatment with targeted agents (TAs) or fludarabine, cyclophosphamide, and rituximab (FCR)-based chemo-immunotherapy (CIT) on overall survival (OS) compared to age- and sex-matched individuals in the general populat... Read More about Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population.

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease (2023)
Journal Article
Munir, T., Cairns, D. A., Bloor, A., Allsup, D., Cwynarski, K., Pettitt, A., …Hillmen, P. (2024). Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine, 390(4), 326-337. https://doi.org/10.1056/NEJMoa2310063

BACKGROUND: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment duration... Read More about Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials (2023)
Journal Article
Molica, S., & Allsup, D. (2023). Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials. Expert Review of Anticancer Therapy, https://doi.org/10.1080/14737140.2023.2288899

Introduction: Chronic lymphocytic leukemia (CLL) management has witnessed a transformative shift with the advent of time-limited venetoclax and anti-CD20 monoclonal antibody (mAb) regimens, as exemplified by the groundbreaking MURANO and CLL14 trials... Read More about Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials.

Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets (2023)
Journal Article
Gil, H. M., Booth, Z., Price, T. W., Lee, J., Naylor‐Adamson, L., Avery, M., …Stasiuk, G. J. (in press). Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets. Small, Article 2304881. https://doi.org/10.1002/smll.202304881

InP/ZnS quantum dots (QDs) have received a large focus in recent years as a safer alternative to heavy metal-based QDs. Given their intrinsic fluorescent imaging capabilities, these QDs can be potentially relevant for in vivo platelet imaging. The In... Read More about Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets.

Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions (2023)
Journal Article
Molica, S., Tam, C., Allsup, D., & Polliack, A. (in press). Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions. Hematological Oncology, https://doi.org/10.1002/hon.3238

In the modern era of Chronic Lymphocytic Leukemia (CLL) targeted therapy, the loss of p53 function due to genetic abnormalities remains a significant challenge. This is because even targeted agents, which are currently the mainstay of treatment for C... Read More about Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial (2023)
Journal Article
Rawstron, A., Webster, N., Dalal, S., de Tute, R. M., Bell, S., Cairns, D. A., …Hillmen, P. (2023). Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial. Blood, 142(Supplement 1), 632-632. https://doi.org/10.1182/blood-2023-187943

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients (2023)
Journal Article
Sarma, A., Evans, C., Dalal, S., Webster, N., Rawstron, A., Shingles, J., …Hillmen, P. (2023). Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients. Blood, 142(Supplement 1), 4636-4636. https://doi.org/10.1182/blood-2023-188597

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study (2023)
Journal Article
Hillmen, P., Cairns, D. A., Bloor, A. J. C., Allsup, D., Cwynarski, K., Pettitt, A., …Munir, T. (2023). Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study. Blood, 142(Supplement 1), 631. https://doi.org/10.1182/blood-2023-178298

Introduction: Ibrutinib (I), an irreversible Btk inhibitor, and venetoclax (V), a Bcl-2 inhibitor, improve CLL outcomes in trials compared to chemoimmunotherapy. I and V target two key pathophysiological pathways in CLL and should be synergistic. Thi... Read More about Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study.

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL (2023)
Journal Article
Visentin, A., Chatzikonstantinou, T., Scarfò, L., Kapetanakis, A., Demosthenous, C., Karakatsoulis, G., …Te Raa, D. (2023). The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL. American Journal of Hematology, 98(12), 1856-1868. https://doi.org/10.1002/ajh.27093

In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytos... Read More about The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option (2023)
Journal Article
Molica, S., Tam, C., Allsup, D., & Polliack, A. (2023). Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option. Cancers, 15(14), Article 3737. https://doi.org/10.3390/cancers15143737

Ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor (BTKi), is a commonly deployed therapeutic option for previously untreated and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia (CLL). The use of ibrutinib is, howev... Read More about Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial (2023)
Journal Article
Hillmen, P., Pitchford, A., Bloor, A., Broom, A., Young, M., Kennedy, B., …Munir, T. (2023). Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The lancet oncology, 24(5), 535-552. https://doi.org/10.1016/S1470-2045%2823%2900144-4

Background: The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients considered unfit for fludara... Read More about Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies (2023)
Journal Article
Khan, S., Allsup, D., & Molica, S. (2023). An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies. Frontiers in Oncology, 13, Article 1135812. https://doi.org/10.3389/fonc.2023.1135812

Chronic lymphocytic leukaemia (CLL) is a malignancy of clonally expanded antigen-switched, neoplastic, mature B cells. CLL is characterised by a variable degree of immunosuppression and secondary hypogammaglobulinemia. B-cell depleting therapies have... Read More about An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies.

Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol (2023)
Journal Article
Baldwin, Z., Busby, S., Allsup, D., Cohen, J., & Bamidele, O. (2023). Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol. PLoS ONE, 18(3), Article e0282458. https://doi.org/10.1371/journal.pone.0282458

Introduction Haematological malignancies are a heterogenous group of blood and lymphatic cancers. Survivorship care is a similarly diverse term concerning patients’ health and wellbeing from diagnosis to end of life. Survivorship care for patients wi... Read More about Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol.

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL (2022)
Journal Article
Antic, D., Milic, N., Chatzikonstantinou, T., Scarfò, L., Otasevic, V., Rajovic, N., …Stamatopoulos, K. (2022). Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. Journal of Hematology & Oncology, 15(1), Article 116. https://doi.org/10.1186/s13045-022-01333-0

BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immu... Read More about Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.

PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia (2022)
Journal Article
Taynton, T., Barlow, G., & Allsup, D. (2022). PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia. JAC-Antimicrobial Resistance, 4(4), Article dlac074. https://doi.org/10.1093/jacamr/dlac074

Mould-active antifungal prophylaxis is frequently used to prevent invasive fungal infection in patients with acute leukaemia being treated with intensive chemotherapy. Invasive fungal infections are difficult to diagnose, and despite the use of proph... Read More about PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia.

A prospective registry-based cohort study of the diagnosis and management of acute leukaemia in pregnancy: Study protocol (2022)
Journal Article
Northgraves, M., Allsup, D., Cohen, J., Huang, C., Turgoose, J., & Ali, S. (2022). A prospective registry-based cohort study of the diagnosis and management of acute leukaemia in pregnancy: Study protocol. PLoS ONE, 17(2), Article e0263195. https://doi.org/10.1371/journal.pone.0263195

Background Acute leukaemias (AL) are aggressive but potentially curable blood cancers that can potentially affect women of childbearing age. When a pregnancy is complicated by a diagnosis of AL, clinicians face a complex dilemma: to balance risking... Read More about A prospective registry-based cohort study of the diagnosis and management of acute leukaemia in pregnancy: Study protocol.

Long‐term follow‐up of 415 patients with chronic lymphocytic leukaemia treated with fludarabine and cyclophosphamide‐based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials, a comprehensive assessment of prognostic factors (2022)
Journal Article
Allsup, D. J., Craig, Z., Cairns, D., Howard, D., Hockaday, A., Bloor, A., …Hillmen, P. (in press). Long‐term follow‐up of 415 patients with chronic lymphocytic leukaemia treated with fludarabine and cyclophosphamide‐based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials, a comprehensive assessment of prognostic factors. American Journal of Hematology, https://doi.org/10.1002/ajh.26483

Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia (2021)
Journal Article
Naylor-Adamson, L., Chacko, A., Booth, Z., Caserta, S., Jarvis, J., Khan, S., …Arman, M. (2021). Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia. Frontiers in immunology, 12, Article 766272. https://doi.org/10.3389/fimmu.2021.766272

Bacterial infections are a major cause of morbidity and mortality in chronic lymphocytic leukemia (CLL), and infection risk increases in patients treated with the Bruton’s tyrosine kinase (Btk) inhibitor, ibrutinib. Btk and related kinases (like Tec)... Read More about Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia.

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study (2021)
Journal Article
Chatzikonstantinou, T., Kapetanakis, A., Scarfò, L., Karakatsoulis, G., Allsup, D., Cabrero, A. A., …Ghia, P. (in press). COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, https://doi.org/10.1038/s41375-021-01450-8

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-d... Read More about COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.

Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (2021)
Journal Article
Lin, W. Y., Fordham, S. E., Hungate, E., Sunter, N. J., Elstob, C., Xu, Y., …Allan, J. M. (2021). Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature communications, 12(1), Article 6233. https://doi.org/10.1038/s41467-021-26551-x

Acute myeloid leukemia (AML) is a hematological malignancy with an undefined heritable risk. Here we perform a meta-analysis of three genome-wide association studies, with replication in a fourth study, incorporating a total of 4018 AML cases and 104... Read More about Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies (2021)
Journal Article
Pepper, A. G., Zucchetto, A., Norris, K., Tissino, E., Polesel, J., Soe, Z., …Pepper, C. (2021). Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, https://doi.org/10.1038/s41375-021-01322-1

Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia (2021)
Journal Article
Molica, S., Allsup, D., Gianfelici, V., Levato, L., Aiello, V., Bailey, J., & Polliack, A. (in press). Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs, https://doi.org/10.1080/13543784.2021.1924669

Introduction: Venetoclax has emerged as a breakthrough treatment which has revolutionized the therapeutic paradigm of chronic lymphocytic leukemia (CLL). This is primarily attributed to the efficacy of venetoclax as a time-limited, chemo-free, therap... Read More about Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia.

Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia (2021)
Journal Article
Lin, W. Y., Fordham, S. E., Sunter, N., Elstob, C., Rahman, T., Willmore, E., …Allan, J. M. (2021). Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. Nature communications, 12(1), Article 665. https://doi.org/10.1038/s41467-020-20822-9

© 2021, The Author(s). Prognostication in patients with chronic lymphocytic leukemia (CLL) is challenging due to heterogeneity in clinical course. We hypothesize that constitutional genetic variation affects disease progression and could aid prognost... Read More about Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia.

Whole-genome sequencing of a sporadic primary immunodeficiency cohort (2020)
Journal Article
Cooper, N., Abbs, S., Farmery, J. H., Deevi, S. V., Thaventhiran, J. E., Adhya, Z., …Smith, K. G. C. (2020). Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature, 583(7814), 90-95. https://doi.org/10.1038/s41586-020-2265-1

Primary immunodeficiency (PID) is characterized by recurrent and often life-threatening infections, autoimmunity and cancer, and it poses major diagnostic and therapeutic challenges. Although the most severe forms of PID are identified in early child... Read More about Whole-genome sequencing of a sporadic primary immunodeficiency cohort.

Targeted removal of blood cancer cells from mixed cell populations by cell recognition with matching particle imprints (2019)
Journal Article
Das, A. A., Remaud, P., Medlock, J., Das, A. A. K., Allsup, D. J., Madden, L. A., …Paunov, V. N. (2019). Targeted removal of blood cancer cells from mixed cell populations by cell recognition with matching particle imprints. Materials Chemistry Frontiers, 4(1), 197-205. https://doi.org/10.1039/c9qm00531e

We report a new approach for separation of blood cancer cells from healthy white blood cells based on cell recognition by surface functionalised particle imprints. We prepared polymeric particle imprints from a layer of suspension of monodisperse PMM... Read More about Targeted removal of blood cancer cells from mixed cell populations by cell recognition with matching particle imprints.

Next-generation sequencing for the diagnosis of MYH9-RD: Predicting pathogenic variants (2019)
Journal Article
Bury, L., Megy, K., Stephens, J. C., Grassi, L., Greene, D., Gleadall, N., …Westbury, S. K. (2020). Next-generation sequencing for the diagnosis of MYH9-RD: Predicting pathogenic variants. Human Mutation, 41(1), 277-290. https://doi.org/10.1002/humu.23927

Human Mutation published by Wiley Periodicals, Inc. The heterogeneous manifestations of MYH9-related disorder (MYH9-RD), characterized by macrothrombocytopenia, Döhle-like inclusion bodies in leukocytes, bleeding of variable severity with, in some ca... Read More about Next-generation sequencing for the diagnosis of MYH9-RD: Predicting pathogenic variants.

Germline selection shapes human mitochondrial DNA diversity (2019)
Journal Article
Wei, W., Tuna, S., Keogh, M. J., Smith, K. R., Aitman, T. J., Beales, P. L., …Chinnery, P. F. (2019). Germline selection shapes human mitochondrial DNA diversity. Science, 364(6442), Article eaau6520. https://doi.org/10.1126/science.aau6520

INTRODUCTION Only 2.4% of the 16.5-kb mitochondrial DNA (mtDNA) genome shows homoplasmic variation at >1% frequency in humans. Migration patterns have contributed to geographic differences in the frequency of common genetic variants, but population... Read More about Germline selection shapes human mitochondrial DNA diversity.

Bioimprint aided cell recognition and depletion of human leukemic HL60 cells from peripheral blood (2019)
Journal Article
Das, A. A., Medlock, J., Liang, H., Nees, D., Allsup, D. J., Madden, L. A., & Paunov, V. N. (2019). Bioimprint aided cell recognition and depletion of human leukemic HL60 cells from peripheral blood. Journal of Materials Chemistry B, 7(22), 3497-3504. https://doi.org/10.1039/c9tb00679f

We report a large scale preparation of bioimprints of layers of cultured human leukemic HL60 cells which can perform cell shape and size recognition from a mixture with peripheral blood mononuclear cells (PBMCs). We demonstrate that the bioimprint-ce... Read More about Bioimprint aided cell recognition and depletion of human leukemic HL60 cells from peripheral blood.

Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology (2018)
Journal Article
Went, M., Sud, A., Speedy, H., Sunter, N. J., Försti, A., Law, P. J., …Houlston, R. S. (2019). Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. Blood Cancer Journal, 9(1), Article 1. https://doi.org/10.1038/s41408-018-0162-8

© 2018, The Author(s). The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma (MM) a... Read More about Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.

Sphingolipid dysregulation due to lack of functional KDSR impairs proplatelet formation causing thrombocytopenia (2018)
Journal Article
Turro, E., Bariana, T. K., Gomez, K., Labarque, V., Heremans, J., Whitehorn, D., …Shamardina, O. (2018). Sphingolipid dysregulation due to lack of functional KDSR impairs proplatelet formation causing thrombocytopenia. Haematologica, 104(4), haematol.2018.204784. https://doi.org/10.3324/haematol.2018.204784

Sphingolipids are fundamental to membrane trafficking, apoptosis and cell differentiation and proliferation. KDSR or 3-keto-dihydrosphingosine reductase is an essential enzyme for de novo sphingolipid synthesis, and pathogenic mutations in KDSR resul... Read More about Sphingolipid dysregulation due to lack of functional KDSR impairs proplatelet formation causing thrombocytopenia.

A comprehensive targeted next-generation sequencing panel for genetic diagnosis of patients with suspected inherited thrombocytopenia (2018)
Journal Article
Johnson, B., Doak, R., Allsup, D., Astwood, E., Evans, G., Grimley, C., …the UK GAPP Study Group. (2018). A comprehensive targeted next-generation sequencing panel for genetic diagnosis of patients with suspected inherited thrombocytopenia. Research and Practice in Thrombosis and Haemostasis, 2(4), 640-652. https://doi.org/10.1002/rth2.12151

Background: Inherited thrombocytopenias (ITs) are a heterogeneous group of disorders characterized by low platelet counts and often disproportionate bleeding with over 30 genes currently implicated. Previously the UK-GAPP study using whole exome sequ... Read More about A comprehensive targeted next-generation sequencing panel for genetic diagnosis of patients with suspected inherited thrombocytopenia.

Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome (2017)
Journal Article
Till, K. J., Allen, J. C., Talab, F., Lin, K., Allsup, D., Cawkwell, L., …Slupsky, J. R. (2017). Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. Scientific reports, 7(1), Article ARTN 16784. https://doi.org/10.1038/s41598-017-17021-w

© 2017 The Author(s). Pathogenesis of chronic lymphocytic leukaemia (CLL) is contingent upon antigen receptor (BCR) expressed by malignant cells of this disease. Studies on somatic hypermutation of the antigen binding region, receptor expression leve... Read More about Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome.

Hematological malignancies in pregnancy (2017)
Book Chapter
Allsup, D., Ali, S., & Robinson, S. (2017). Hematological malignancies in pregnancy. In D. James, P. Steer, C. Weiner, B. Gonik, & S. Robson (Eds.), High-Risk Pregnancy: Management Options (1006-1043). Cambridge University Press

The diagnosis of a hematological malignancy during pregnancy poses a major challenge to the pregnant woman, her family, and the medical team. Treatment of a pregnant woman with chemotherapy poses a risk to the fetus and raises therapeutic, ethical, a... Read More about Hematological malignancies in pregnancy.

The use of ofatumumab in the treatment of B-cell malignancies (2017)
Journal Article
Soe, Z. N., & Allsup, D. (2017). The use of ofatumumab in the treatment of B-cell malignancies. Future oncology, 13(29), 2611-2628. https://doi.org/10.2217/fon-2017-0275

Ofatumumab has been extensively studied in the treatment of B-cell malignancies. Currently, it has been approved for the treatment of chronic lymphocytic leukemia in a number of different situations. However, there is still no compelling evidence con... Read More about The use of ofatumumab in the treatment of B-cell malignancies.

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial (2017)
Journal Article
Collett, L., Howard, D. R., Munir, T., McParland, L., Oughton, J. B., Rawstron, A. C., …Hillmen, P. (2017). Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials, 18(1), Article 387. https://doi.org/10.1186/s13063-017-2138-6

Background Treatment of chronic lymphocytic leukaemia (CLL) has seen a substantial improvement over the last few years. Combination immunochemotherapy, such as fludarabine, cyclophosphamide and rituximab (FCR), is now standard first-line therapy. How... Read More about Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.

Cancer bioimprinting and cell shape recognition for diagnosis and targeted treatment (2017)
Journal Article
Medlock, J., Das, A. A. K., Madden, L. A., Allsup, D. J., & Paunov, V. N. (2017). Cancer bioimprinting and cell shape recognition for diagnosis and targeted treatment. Chemical Society Reviews, 46(16), 5110-5127. https://doi.org/10.1039/c7cs00179g

Cancer incidence and mortality have both increased in the last decade and are predicted to continue to rise. Diagnosis and treatment of cancers are often hampered by the inability to specifically target neoplastic cells. Bioimprinting is a promising... Read More about Cancer bioimprinting and cell shape recognition for diagnosis and targeted treatment.

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma (2017)
Journal Article
Pratt, G., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., …Stankovic, T. (2018). A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. British journal of haematology, 182(3), 429-433. https://doi.org/10.1111/bjh.14793

Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL (2017)
Journal Article
Howard, D. R., Munir, T., McParland, L., Rawstron, A. C., Milligan, D., Schuh, A., …Hillmen, P. (2017). Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 31(11), 2416-2425. https://doi.org/10.1038/leu.2017.96

© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. ARCTIC was a multicenter, randomized-controlled, open, phase IIB non-inferiority trial in previously untreated chronic lymphocytic leukemia (CLL). Conventional frontli... Read More about Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.

Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia (2017)
Journal Article
Law, P. J., Berndt, S. I., Speedy, H. E., Camp, N. J., Sava, G. P., Skibola, C. F., …Slager, S. (2017). Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature communications, 8, 14175. https://doi.org/10.1038/ncomms14175

Several chronic lymphocytic leukaemia (CLL) susceptibility loci have been reported; however, much of the heritable risk remains unidentified. Here we perform a meta-analysis of six genome-wide association studies, imputed using a merged reference pan... Read More about Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia.

Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci (2017)
Journal Article
Law, P. J., Sud, A., Mitchell, J. S., Henrion, M., Orlando, G., Lenive, O., …Houlston, R. S. (2017). Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. Scientific reports, 7, 41071. https://doi.org/10.1038/srep41071

B-cell malignancies (BCM) originate from the same cell of origin, but at different maturation stages and have distinct clinical phenotypes. Although genetic risk variants for individual BCMs have been identified, an agnostic, genome-wide search for s... Read More about Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial (2016)
Journal Article
Howard, D. R., Munir, T., Hockaday, A., Rawstron, A. C., Collett, L., Oughton, J. B., …Hillmen, P. (2016). Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. Trials, 17(1), Article 456. https://doi.org/10.1186/s13063-016-1581-0

Background: Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Combination immunochemotherapy such as fludarabine, cyclophosphamide and rituximab is the standard first line therapy in fit patients, but there is limited evidence r... Read More about Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.

Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects (2016)
Journal Article
Johnson, B., Lowe, G. C., Futterer, J., Lordkipanidzé, M., Macdonald, D., Simpson, M. A., …on behalf of the UK GAPP Study Group. (2016). Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects. Haematologica, 101(10), 1170-1179. https://doi.org/10.3324/haematol.2016.146316

© 2016 Ferrata Storti Foundation. Inherited thrombocytopenias are a heterogeneous group of disorders characterized by abnormally low platelet counts which can be associated with abnormal bleeding. Next-generation sequencing has previously been employ... Read More about Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects.

Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease (2014)
Journal Article
Lin, T. T., Norris, K., Heppel, N. H., Pratt, G., Allan, J. M., Allsup, D. J., …Pepper, C. (2014). Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. British journal of haematology, 167(2), 214-223. https://doi.org/10.1111/bjh.13023

© 2014 John Wiley & Sons Ltd. Defining the prognosis of individual cancer sufferers remains a significant clinical challenge. Here we assessed the ability of high-resolution single telomere length analysis (STELA), combined with an experimentally d... Read More about Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease.

A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia (2013)
Journal Article
Speedy, H. E., Di Bernardo, M. C., Sava, G. P., Dyer, M. J. S., Holroyd, A., Wang, Y., …Houlston, R. S. (2014). A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nature genetics, 46(1), 56-60. https://doi.org/10.1038/ng.2843

Genome-wide association studies (GWAS) of chronic lymphocytic leukemia (CLL) have shown that common genetic variation contributes to the heritable risk of CLL. To identify additional CLL susceptibility loci, we conducted a GWAS and performed a meta-a... Read More about A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia.

Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen (2013)
Journal Article
Kashuba, E., Eagle, G. L., Bailey, J., Evans, P., Welham, K. J., Allsup, D., & Cawkwell, L. (2013). Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen. Journal of Proteomics, 91, 478-485. https://doi.org/10.1016/j.jprot.2013.08.002

CLL is an incurable disease with variable prognosis. The hyper reactivity of the B-cell receptor (BCR) to unknown antigen ligation plays a pivotal role in CLL-cell survival. We aimed to investigate the BCR signalling pathway using proteomics to ident... Read More about Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen.

The kinin–kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers (2013)
Journal Article
Kashuba, E., Bailey, J., Allsup, D., & Cawkwell, L. (2013). The kinin–kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers. Biomarkers, 18(4), 279-296. https://doi.org/10.3109/1354750x.2013.787544

The kinin–kallikrein system (KKS) is an endogenous multiprotein cascade, the activation of which leads to triggering of the intrinsic coagulation pathway and enzymatic hydrolysis of kininogens with the consequent release of bradykinin-related peptide... Read More about The kinin–kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers.

The automated monocyte count is independently predictive of overall survival from diagnosis in chronic lymphocytic leukaemia and of survival following first-line chemotherapy (2013)
Journal Article
Mazumdar, R., Evans, P., Culpin, R., Bailey, J., & Allsup, D. (2013). The automated monocyte count is independently predictive of overall survival from diagnosis in chronic lymphocytic leukaemia and of survival following first-line chemotherapy. Leukemia Research, 37(6), 614-618. https://doi.org/10.1016/j.leukres.2013.02.020

We conducted an analysis of the effect of monocytosis at diagnosis of CLL on subsequent overall (OS) and treatment-free survival (TFS). Monocyte counts were performed using the Sysmex XE2100™ analyser. A monocyte count >0.91×109L-1 at the time of dia... Read More about The automated monocyte count is independently predictive of overall survival from diagnosis in chronic lymphocytic leukaemia and of survival following first-line chemotherapy.

Increased inducible heat shock protein 72 expression associated with PBMC isolated from patients with haematological tumours (2012)
Journal Article
Madden, L. A., Hayman, Y. A., Underwood, C., Vince, R. V., Greenman, J., Allsup, D., & Ali, S. (2012). Increased inducible heat shock protein 72 expression associated with PBMC isolated from patients with haematological tumours. Scandinavian journal of clinical & laboratory investigation, 72(5), 380-386. https://doi.org/10.3109/00365513.2012.681683

Background. Heat shock protein 72 (Hsp72) is a highly inducible stress protein and molecular chaperone. Cancers have been shown to be associated with increased Hsp72 expression within the tumour itself and this may lead to resistance to apoptosis. Me... Read More about Increased inducible heat shock protein 72 expression associated with PBMC isolated from patients with haematological tumours.

Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism (2010)
Journal Article
Whittle, A. M., Allsup, D. J., & Bailey, J. R. (2011). Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism. Leukemia Research, 35(3), 419-421. https://doi.org/10.1016/j.leukres.2010.11.011

Venous thromboembolism (VTE) is a major cause of morbidity and mortality in cancer patients. The literature is sparse on the incidence in the most common lymphoid malignancy, chronic lymphocytic leukaemia (CLL). We calculated the incidence rates for... Read More about Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism.

Thalidomide enhances cyclophosphamide and dexamethasone-mediated cytotoxicity towards cultured chronic lymphocytic leukaemia cells (2010)
Journal Article
Pointon, J. C., Eagle, G., Bailey, J., Evans, P., Allsup, D., & Greenman, J. (2010). Thalidomide enhances cyclophosphamide and dexamethasone-mediated cytotoxicity towards cultured chronic lymphocytic leukaemia cells. Oncology Reports, 24(5), 1315-1321. https://doi.org/10.3892/or_00000988

Numerous chemotherapeutic regimens exist for the treatment of symptomatic or progressive chronic lymphocytic leukaemia (CLL). However, once the disease becomes refractory to nucleoside-based therapy the prognosis is poor. In this study we investigate... Read More about Thalidomide enhances cyclophosphamide and dexamethasone-mediated cytotoxicity towards cultured chronic lymphocytic leukaemia cells.